Stuart Holden
Urology · Los Angeles, CANPI 1013941483
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,044,877 of the $1,065,464 with a category attached, or 98.1%. Urogen Pharma, Inc. accounts for 99.9% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $397,337, 2.0 times the $195,168 reported in 2021. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $10,052 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$1.1M
- Rochester Medical Corporation$378
- C. R. Bard, Inc. & Subsidiaries$184
- BD$27
What the payments were for
- Speaking & faculty fees$1,044,87798%
- Travel & lodging$18,0762%
- Food & beverage$2,5120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 54 | $1,064,875 |
| Rochester Medical Corporation | 34 | $378 |
| C. R. Bard, Inc. & Subsidiaries | 16 | $184 |
| BD | 2 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JELMYTO$478
How this compares
$1,065,464 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 61 | $6,128 |
| Finasteride | 140 | $2,562 |
| Tamsulosin Hcl | 130 | $1,954 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 13 | $369 |
| Prednisone | 32 | $171 |
Paid to pharmacies, not to this prescriber.
Other urology in Los Angeles
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- William AronsonLos Angeles$540K
- Amir LebastchiLos Angeles$478K
- Nazy ZomorodianLos Angeles$309K
- Jeffrey Loh-DoyleLos Angeles$308K
- Siamak DaneshmandLos Angeles$306K
- Karim ChamieLos Angeles$291K
- Brian ShuchLos Angeles$166K
- Robert ReiterLos Angeles$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.